NIH Front-Loaded $402M Of FY2026 Money Into 601 Multiyear Grants By Mid-May. The Mechanical Result Is 66% Fewer New Awards For Everyone Else.

A pattern that started as a niche budget-management tool at the National Institutes of Health has, in the first half of FY2026, become the central determinant of who gets funded this year and who does not. As of mid-May 2026, NIH has awarded 601 multiyear grants totaling $402 million — compared to 162 grants and $79 million at the same point in FY2025, and 146 grants and $75 million at the same point in FY2024. That is a 271% jump in early-cycle multiyear awards and a 409% jump in early-cycle dollars obligated through multiyear vehicles, in a single year.

The Association of American Universities recently reported that NIH issued 66% fewer total grant awards in the first few months of 2026 than in the same period of 2025. The two numbers are not unrelated; they are mechanically connected. When NIH forward-funds a five-year R01 at the beginning of the fiscal year, the dollars for years two through five come out of the FY2026 obligational authority all at once, not over the life of the grant. That money is then unavailable for new awards in the remainder of FY2026 — and the resulting compression has consequences that are now showing up in Ph.D. enrollment decisions, lab hiring plans, and the funding strategies of every research-intensive university in the country.

This is the deep analysis of what multiyear funding does, why NIH has accelerated it, what the FY2027 budget request implies for the next cycle, and what investigators applying for R01, R21, K, and U awards should do differently as a result.

What multiyear funding actually is

The standard NIH research grant is awarded as a noncompeting continuation in years two through five (or two through three for an R21, two through five for most R01s, longer for some U awards and SCOREs). NIH commits to the multi-year project at the time of award but obligates the dollars one fiscal year at a time. In a typical year, year-one funds come out of the FY in which the award is made, year-two funds come out of the next FY, and so on. The mechanism gives NIH flexibility to manage budget shifts year over year and gives the appropriations committee an ongoing instrument for course correction.

A multiyear-funded grant breaks this pattern. NIH obligates all years of the award at the time of the initial award, drawing the entire multi-year cost out of a single fiscal year's appropriation. The mechanism has existed for decades and has historically been used in narrow circumstances — for example, grants to international collaborators where the U.S. side cannot guarantee future-year dollars, or end-of-fiscal-year obligations where unspent funds would otherwise lapse.

In FY2024, NIH awarded 1,067 multiyear grants totaling $960 million across the full fiscal year — roughly 3% of all extramural obligations. In FY2025, that grew to over 2,000 grants totaling $2.2 billion, or 6% of all extramural obligations. The mid-May 2026 numbers — 601 grants and $402 million obligated in the first eight months — put the FY2026 trajectory on pace to potentially double the FY2025 figure, with the additional change that the awards are now concentrated at the front of the fiscal year rather than at year-end.

The NIH FY2027 budget proposal makes the trend explicit. It requests authority to forward-fund "all competing research project grant awards," describing the change as a tool for "budget flexibility." If granted, that authority would convert the historical default for NIH funding from year-by-year obligation to up-front multiyear obligation — for every R01, R21, R35, R37, P01, U01, U54, and every other competing project grant the agency funds.

Why this is mechanically squeezing FY2026 awards

The math of forward-funding is unforgiving. If NIH funds an average R01 at $500,000 per year for five years and forward-funds it at the start of FY2026, $2.5 million leaves the FY2026 budget at the time of award. Under the historical model, the same grant would consume $500,000 from FY2026 and the remaining $2 million from FY2027 through FY2030 as those appropriations were enacted.

Multiply across thousands of grants and the effect compounds. If 1,000 multiyear-funded R01s issue in the first half of FY2026 at an average forward-fund of $1.5 million each, that pulls $1.5 billion out of the FY2026 obligational pool that would otherwise have been available for additional new awards in the second half of the fiscal year. The number of new grants funded in the second half necessarily contracts.

This is what AAU is measuring when it reports a 66% year-over-year contraction in early-2026 NIH grant awards. The agency is not necessarily spending less money in FY2026 — though Congressional appropriations have also tightened — but it is spending it on a smaller number of larger commitments, and the institutional consequences land disproportionately on early-career investigators, first-time R01 applicants, and labs with no current grant whose next funding decision depends on a new-award cycle that has effectively shrunk.

Heather Pierce, senior director at the Association of American Medical Colleges, framed the concern directly: "The concern is that a very rapid shift to using multiyear funding for the vast majority — or all — research grants decreases precipitously the number of grants you can fund." Lizbet Boroughs of AAU added the structural framing: "Fewer shots on goal, that is fewer chances for discovery, for diagnostics, for treatments and for cures."

The Ph.D. enrollment and lab-hiring consequence

The mid-May 2026 contraction is no longer abstract — it is now visible in academic personnel decisions. Universities, particularly research-intensive medical schools and Ph.D.-granting biomedical programs, are reporting that they are not accepting as many Ph.D. students in the 2026–27 admissions cycle as they did in 2024 or 2025. The mechanism is straightforward: a Ph.D. student in a wet-lab biomedical field is typically supported on a faculty member's research grant for several years of dissertation work. A PI whose R01 was not renewed in early 2026 — or who did not win a new R01 because the new-award pool contracted — cannot commit to supporting a new student for the next five years.

The downstream effect is delayed but predictable. A 20% contraction in Ph.D. admissions in 2026 translates into a 20% smaller cohort of senior postdocs in 2031 and a 20% smaller pool of K99/R00 candidates in 2032. The training pipeline does not refill quickly, and the consequences of the FY2026 squeeze will be felt in the FY2031 K-award round whether or not multi-year forward-funding remains the dominant mechanism.

Lab hiring is moving in parallel. Senior postdoc hires are being delayed; technician searches are being postponed; the conversion of soft-money instructor positions into tenure-track lines is slowing. None of these effects are publicly tracked the way NIH paylines are, but they show up in the operating margins of research-intensive medical schools and in the lab-by-lab decisions PIs are making about who they can afford to bring on.

What investigators should do differently in FY2026 and FY2027

The strategic implication of multiyear forward-funding is that the probability of success at any given application cycle is now more variable than the historical payline implied. An investigator submitting a competing R01 in a cycle where the institute has recently forward-funded a large block of multiyear awards is competing for a smaller pool of dollars than the historical baseline would suggest. The same investigator submitting the same application in a cycle where the institute is replenishing its pool of unobligated balances may face a more favorable payline.

Four practical adjustments:

First, monitor institute-specific funding patterns, not the agency-wide payline. NIH publishes funding data at the institute and center level, and the mix of multiyear vs. year-by-year obligation varies considerably across NIAID, NCI, NHLBI, NIGMS, and the smaller ICs. The institute most relevant to a particular grant may be running a more or less aggressive forward-funding posture than NIH as a whole.

Second, plan for longer time-to-award. Even when an application is funded, the administrative processing of a multiyear award can take longer than a single-year award because NIH has to certify the full multi-year obligation up front. Applicants should plan project start dates with two-to-three additional months of buffer compared to the historical timeline.

Third, diversify away from NIH where the science permits. Investigators whose research can credibly fit DOD CDMRP topics, DOE Office of Science programs, foundation calls (CZI, Wellcome Leap, Howard Hughes), or NSF Biological Sciences should treat the FY2026 squeeze as a forcing function to build relationships with program officers at non-NIH funders before the next cycle. The cost of cultivating those relationships is now lower than the expected return.

Fourth, treat resubmission strategy more aggressively. With fewer new awards in each cycle, the gap between a fundable score and a not-quite-fundable score narrows. Resubmissions that address reviewer concerns substantively — not cosmetically — have a higher relative return than they did at historical paylines, because the marginal application that just missed the cutoff is now competing in a tighter field where small improvements move the needle more.

What to watch for in the FY2027 appropriations debate

The NIH FY2027 budget request's explicit ask for forward-funding authority across all competing research project grants is the single most important policy lever to track over the next twelve months. If Congress grants the authority, the forward-funding pattern visible in early FY2026 becomes the structural default for the entire program. If Congress declines or imposes constraints — for example, capping forward-funding at a percentage of total obligational authority, or requiring agency-by-agency justifications — the pattern reverses and the new-award pool stabilizes.

Watch for three signals. First, House and Senate appropriations committee report language on NIH forward-funding authority in the FY2027 Labor-HHS-Ed bills. Second, NIH guide notices in the second half of calendar 2026 that quantify the share of competing awards being forward-funded. Third, paylines published by individual institutes in the FY2027 first quarter, which will signal whether the squeeze is structural or transient.

The OMB Uniform Guidance proposal published on May 29, 2026 (Granted analysis) overlays additional uncertainty on top of the multiyear funding shift — both changes affect the same applicant population in the same fiscal year. Investigators who model their FY2026 and FY2027 funding strategies on the FY2024 payline are using an obsolete map. The pool has shrunk, the obligation timing has shifted, and the political-appointee discretion in grant termination has expanded. None of this is a reason to stop submitting applications; it is a reason to submit smarter ones and to spread the bets across funders, mechanisms, and resubmission cycles.

Sources

• NIH's Use of "Multiyear Funding" Grants Poses Research Risks — Inside Higher Ed
• Federal funding delays are harming science irreparably, researchers say — NPR
• Trump administration seeks to overhaul federal grantmaking process — STAT News
• NIH Grants and Funding Information Status
• NIH's Path to a Simpler Funding Opportunity Landscape
• OMB Uniform Guidance Overhaul Analysis — Granted